BofA warns Fed risks policy mistake with early rate cuts
On Monday, Piper Sandler analysts increased their price target for Replimune Group stock to $22 from $14, while maintaining an Overweight rating. The adjustment follows several recent updates from the company and comes as the stock shows strong momentum, with a 7.54% gain over the past week and an impressive 70.4% return over the last year. According to InvestingPro data, analyst targets for REPL range from $16 to $31, suggesting significant potential upside.
Replimune Group (NASDAQ: REPL) recently disclosed additional RP1 data at the ASCO conference and released its FY4Q25/YE25 report. Piper Sandler analysts cited these developments as key factors in their decision to raise the price target. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt on its balance sheet, though it’s currently unprofitable. Want deeper insights? InvestingPro offers 8 additional key tips about REPL’s financial health and market position.
The analysts also highlighted a July 22 PDUFA date for RP1, noting that the FDA does not expect an AdCom meeting. This timeline remains on track, according to the analysts, who also hosted a melanoma KOL event and investor meetings with Replimune management last week.
Piper Sandler expressed confidence in Replimune’s commercial preparedness and adjusted their market outlook to reflect anticipated market dynamics and pricing. The analysts continue to view the risk/reward profile for RP1 as favorable, despite some investor skepticism about its approvability.
In other recent news, Replimune Group Inc (NASDAQ:REPL). reported its first-quarter earnings for 2025, revealing a significant miss on expected earnings per share (EPS). The company posted an EPS of -$3.07, which was notably below the forecasted -$0.72. Despite the earnings miss, Replimune’s cash and cash equivalents rose to $483.8 million, providing a cash runway into the fourth quarter of 2026. The company is preparing for the potential commercialization of its product, RP-one, which has received breakthrough therapy designation and a PDUFA date set for July 2025. Replimune is also expanding its operations with a new manufacturing facility and a 60-person commercial team. Analysts from firms like JPMorgan and Jefferies have shown interest in the company’s upcoming plans and regulatory interactions. Replimune’s leadership remains confident in the market potential of RP-one, particularly for advanced melanoma patients, pending FDA approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.